2023
CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
Han R, Li J, Hony J, Xiao Z, wang J, Yao M, Liang S, Lu L. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Frontiers In Immunology 2023, 14: 1052657. PMID: 37006233, PMCID: PMC10061011, DOI: 10.3389/fimmu.2023.1052657.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, HepatocellularHumansImmune Checkpoint InhibitorsLigandsLiver NeoplasmsTumor MicroenvironmentConceptsImmune checkpoint inhibitorsC motif chemokine ligand 8Hepatocellular carcinomaCheckpoint inhibitorsDeath ligand 1 (PD-L1) immunotherapyCell death protein 1Treatment of HCCDeath protein 1Chemokine ligand 8Function of monocytesTumor immunosuppression microenvironmentClinical benefitCombination therapyImmunosuppression microenvironmentLethal malignancyTherapeutic effectEffective treatmentHCC treatmentAdvanced stageProtein 1Ligand 8ImmunotherapyTreatmentXII inhibitorsAnticancer drugs
2022
Oral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularCase-Control StudiesCyanobacteriaFemaleHumansLiver NeoplasmsMaleMiddle AgedMouthRisk FactorsUnited StatesConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2020
Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study
Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study. Cancer Causes & Control 2020, 31: 321-332. PMID: 32060838, PMCID: PMC7136513, DOI: 10.1007/s10552-020-01277-1.Peer-Reviewed Original ResearchConceptsRisk of HCCCase-control studyHepatocellular carcinomaRisk factorsHCV infectionHCC riskOdds ratioHepatitis C virus antibodyUnconditional logistic regression modelsElevated HCC riskRapid case ascertainmentC virus antibodyHeavy alcohol intakeConfidence intervalsFamily cancer historyImportant risk factorRandom digit dialingLow socioeconomic statusUnhealthy lifestyle choicesLower household incomeLogistic regression modelsNSAID useAlcohol intakeCigarette smokingHigher BMI